Jab1 antibody [2A10.8]
GTX70203
ApplicationsImmunoFluorescence, ImmunoPrecipitation, Western Blot, ImmunoCytoChemistry, ImmunoHistoChemistry
Product group Antibodies
TargetCOPS5
Overview
- SupplierGeneTex
- Product NameJab1 antibody [2A10.8]
- Delivery Days Customer9
- Application Supplier NoteWB: 1:500-1:3000. IP: 0.5 - 1 microg/ml. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
- ApplicationsImmunoFluorescence, ImmunoPrecipitation, Western Blot, ImmunoCytoChemistry, ImmunoHistoChemistry
- CertificationResearch Use Only
- ClonalityMonoclonal
- Clone ID2A10.8
- Concentration1 mg/ml
- ConjugateUnconjugated
- Gene ID10987
- Target nameCOPS5
- Target descriptionCOP9 signalosome subunit 5
- Target synonymsCSN5, JAB1, MOV-34, SGN5, COP9 signalosome complex subunit 5, 38 kDa Mov34 homolog, COP9 constitutive photomorphogenic homolog subunit 5, jun activation domain-binding protein 1, signalosome subunit 5, testis secretory sperm-binding protein Li 231m
- HostMouse
- IsotypeIgG2b
- Protein IDQ92905
- Protein NameCOP9 signalosome complex subunit 5
- Scientific DescriptionThe protein encoded by this gene is one of the eight subunits of COP9 signalosome, a highly conserved protein complex that functions as an important regulator in multiple signaling pathways. The structure and function of COP9 signalosome is similar to that of the 19S regulatory particle of 26S proteasome. COP9 signalosome has been shown to interact with SCF-type E3 ubiquitin ligases and act as a positive regulator of E3 ubiquitin ligases. This protein is reported to be involved in the degradation of cyclin-dependent kinase inhibitor CDKN1B/p27Kip1. It is also known to be an coactivator that increases the specificity of JUN/AP1 transcription factors. [provided by RefSeq, Jul 2008]
- Storage Instruction-20°C or -80°C,2°C to 8°C
- UNSPSC12352203
References
- Zhang Z, Li N, Liu S, et al. Overexpression of IFIT2 inhibits the proliferation of chronic myeloid leukemia cells by regulating the BCR‑ABL/AKT/mTOR pathway. Int J Mol Med. 2020,45(4):1187-1194. doi: 10.3892/ijmm.2020.4500Read this paper
- Wang S, Oh DY, Leventaki V, et al. MicroRNA-17 acts as a tumor chemosensitizer by targeting JAB1/CSN5 in triple-negative breast cancer. Cancer Lett. 2019,465:12-23. doi: 10.1016/j.canlet.2019.08.016Read this paper
- Dubiel D, Bintig W, Kähne T, et al. Cul3 neddylation is crucial for gradual lipid droplet formation during adipogenesis. Biochim Biophys Acta Mol Cell Res. 2017,1864(8):1405-1412. doi: 10.1016/j.bbamcr.2017.05.009Read this paper
- Choi HH, Phan L, Chou PC, et al. COP1 enhances ubiquitin-mediated degradation of p27Kip1 to promote cancer cell growth. Oncotarget. 2015,6(23):19721-34.Read this paper
- Jumpertz S, Hennes T, Asare Y, et al. The β-catenin E3 ubiquitin ligase SIAH-1 is regulated by CSN5/JAB1 in CRC cells. Cell Signal. 2014,26(9):2051-9. doi: 10.1016/j.cellsig.2014.05.013Read this paper
- Merk M, Zierow S, Leng L, et al. The D-dopachrome tautomerase (DDT) gene product is a cytokine and functional homolog of macrophage migration inhibitory factor (MIF). Proc Natl Acad Sci U S A. 2011,108(34):E577-85. doi: 10.1073/pnas.1102941108Read this paper
- McCall CM, Miliani de Marval PL, Chastain PD 2nd, et al. Human immunodeficiency virus type 1 Vpr-binding protein VprBP, a WD40 protein associated with the DDB1-CUL4 E3 ubiquitin ligase, is essential for DNA replication and embryonic development. Mol Cell Biol. 2008,28(18):5621-33. doi: 10.1128/MCB.00232-08Read this paper
- Yun J, Tomida A, Andoh T, et al. Interaction between glucose-regulated destruction domain of DNA topoisomerase IIalpha and MPN domain of Jab1/CSN5. J Biol Chem. 2004,279(30):31296-303.Read this paper
- Doronkin S, Djagaeva I, Beckendorf SK. CSN5/Jab1 mutations affect axis formation in the Drosophila oocyte by activating a meiotic checkpoint. Development. 2002,129(21):5053-64.Read this paper
- Korbonits M, Chahal HS, Kaltsas G, et al. Expression of phosphorylated p27(Kip1) protein and Jun activation domain-binding protein 1 in human pituitary tumors. J Clin Endocrinol Metab. 2002,87(6):2635-43.Read this paper


